Airline plastic Meal Box Mould,Aviation plastic knife and fork Mould,Airline tableware injection mould,Airline Tableware Plastic Mould Dongguan Hongke Plastic Precision Mould Co.,Limited , https://www.hongkemolds.com
Affected by the frequent rise in the price of penicillin industrial salt, the market price of cefaclor has also reached a high level.
The data from the two major medical information magazines, Scrip and Market.Letter from the United States, show that from 1987 to 1997, cefaculo was ranked in the top 10 best-selling drugs in the world for 10 consecutive years, becoming the first best-selling antibiotic, and in the amount and retail sales of doctors. Pharmacy sales topped the category of antimicrobials. According to statistics, the annual consumption of cefaclor in the world exceeded 400 tons in 1993 and increased to 450 tons in 1996; the annual sales of its preparations remained at 1 billion to 1.1 billion US dollars.
Today, the cefaclor patent has expired. In addition to the American Eli Lilly Inc. and Shion Yee Japan Pharmaceuticals, its suppliers include the Italian company ACS Dobfar (a subsidiary of Roussel-Uclaf Biochemicals, France) and the Indian company Ranbaxy. . About 11 domestic producers of Cefaclor raw materials have obtained approvals. Major manufacturers include Guangzhou Baiyunshan, Suzhou Zhonglian and Zhejiang Ang Likang; the earliest approval was obtained from Shandong Xinhua-Kenfu Pharmaceutical Co., Ltd. in 2002. No company has registered since 2005.
The competition for generic drugs has caused caffeine prices to go down, but considering the other side, it is also conducive to its market expansion. It is estimated that the world total sales of cefaclor will still have room for growth in the future.
Rise to 2450 to 2500 yuan/kg, the raw material drug market is becoming increasingly fierce
In recent years, since the key technology of 7-ACCA, an upstream intermediate of cefaclor, has not achieved a breakthrough in the country so far, China has almost no advantage in this international market. Most of the raw materials of cefaclor used in China have come from India. India has mastered key production technologies for the intermediates of cefaclor. At present, there are about 78 domestic companies that supply imported products of Cefaculo, which are basically Indian products. According to statistics, in 2006, China's imports of cefaclor was 42 tons, an increase of 8% year-on-year; imports of 7-ACCA were 43 tons, an increase of 45.52% year-on-year.
Since last year, the price of penicillin industrial salt has attracted much attention. From January 2007 to March this year, the price curve has basically undergone wave-like changes, which in turn has caused the price of cefaclor to fluctuate all the way, and it has now risen to 2450 to 2500 yuan. Kg. The reason may be that some of the raw material vendors are trying to increase the price of the year before and the rise of penicillin industrial salt will raise the price up.
Now that the price of penicillin industrial salt is falling, it is estimated that the price of cefaclor will also go down. Together with the entry of new companies, the competition in this market will become more intense in the future.
The hospital drug is optimistic, the preparation market has steadily increased
In February 1994, Cefaclor was successfully developed in China for the first time. It was first listed by Shandong Zibo Xinda Pharmaceutical Co., Ltd. and its trade name was Xindaro. In the following years, due to the unanimous view of the market prospects of cefaclor, China quickly set off an upsurge in the development of cefaclor.
In 2006, there were 45 cefaclor production enterprises. The main domestic manufacturers include Shandong Zibo Xinda Pharmaceutical, Harbin Yuheng Pharmaceutical, Hainan Sanye Pharmaceutical, Guangzhou Baiyunshan Guanghua Pharmaceutical Company, Suzhou No. 3 Pharmaceutical Factory, Sichuan Pharmaceutical Preparation Company, Zhejiang Asia Pacific Pharmaceutical, Kunming Beckton Norton Pharmaceuticals and so on. Among them, granules (dry suspensions, dry syrups) are produced by Shandong Zibo Xinda Pharmaceutical, Shanghai Miyu Pharmaceutical, Suzhou Zhonghua Pharmaceutical Industrial Company, Guangzhou Baiyunshan, Shantou Jinshi Pharmaceutical Factory, etc.; Sustained-release tablet production plants Shandong Zibo Xinda Pharmaceutical, Zhejiang Ang Likang Pharmaceutical and so on. In the hospital market, cefaclor capsules and granules were included in the first batch of national basic medical insurance and industrial injury insurance drug catalogs. In 2004, when the medical insurance list was revised, sustained-release tablets were included, thus promoting cefaclor antibiotics in 2007. The growth rate of the hospital drug market is as high as 35%, ranking the top ten in the market growth rate of antibiotics.
At present, cefaclor in clinical use mainly has two specifications of 250 mg capsules and 125 mg granules. China Chemical Industry Association statistics show that in the first half of 2008, the total output of 250 mg of Cefaclor capsules was 51.98 million, and the production of granules was 56.664 million bags.
Capsule production is mainly concentrated in the top three companies, namely Shandong Zibo Xinda Pharmaceutical, Shanghai Hyundai and Suzhou No. 3 Pharmaceuticals, with a market concentration of 43.7%. The production of granules was mainly concentrated in Shandong Zibo Xinda Pharmaceutical and Guangzhou Baiyunshan. The output of the two companies accounted for nearly 77% of the total granule production, of which Xinda Pharmaceutical had a share of more than 50%.
It is understood that in 2006, Xinda Pharmaceutical and Zhejiang Ang Likang developed a new dosage form of sustained-release tablets with a specification of 375mg, of which Xinda Pharmaceutical had reached 2.42 million tablets in the first half of this year.
Prospects can be expected
- The overall market for cefaclor entered the equilibrium period. In the first half of this year, the ranking of the top ten manufacturing companies was basically the same as that of 2006. Among the top ten manufacturers, except for the market share of Xijiao Lai of Suzhou Lilly and Sundiro of Xinda Pharmaceutical, the output of the companies ranked behind this year was basically the same as last year.
- Cefaclor products have been divided into two camps: First, as the original drug Xijiao Lao, which is priced separately, the current capsule (0.25g * 12 tablets) retail price of 99 yuan / box, dry suspension ( 0.125g*6 bag) is 33.9 yuan/carton. Due to its early listing, this brand has a strong position in key hospitals in major cities.
The other party is a national product. After several price cuts, the prices of domestic cefaclor were: capsules/tablets (0.25g*12 tablets) 50.5 yuan/box, granules (0.125g*6 bags) 16.5 yuan/box, sustained-release tablets 0.375g*6 51 yuan/box. In general, the domestic cefaclor market is fiercely competitive. In addition to the fight between domestic companies, it also faces competition from joint ventures.
——Because of its advantages such as convenience in oral administration, the overall market size of Cefaclor will continue to expand, especially in children's medicine. According to the monitoring of the National Medical Economic Information Network, from 2005 to 2007, the prescription of cephalosporin antibiotics in pediatrics in more than 60 sample hospitals in Beijing, Guangzhou, Tianjin, and Hangzhou has increased significantly, among them, cefaclor, cefuroxime, and cefixime. The other four species grew the most. These products are mainly used in respiratory infections, followed by urinary tract infections.
Due to the presence of quinolones in cartilage toxicity and liver and kidney toxicity, it is forbidden to be used in patients under the age of 18. Penicillins and macrolides also limit the application in pediatrics because of skin test problems and gastrointestinal irritation problems, respectively. Crowe and other cephalosporin antibiotics have good efficacy and safety for common pathogens, so their prescriptions in the pediatric market are gradually expanding.
It is foreseeable that some oral antibiotic products that are easy to take and affordable will be increasingly welcomed by medical personnel and patients. Cefaclor, after two price adjustments, prices have been accepted by most patients, and this product has been more mature after many years of clinical application. These conditions have determined that the product has a promising market and contains a large space for growth.
The adjusted price can be accepted by most patients and the clinical maturity gradually increases. Therefore, the growth rate in antibiotics has been good in recent years, which in turn encourages manufacturers to continuously develop new specifications and new dosage forms.